Literature DB >> 27208428

Opposing roles of TGF-β and EGF in the regulation of TRAIL-induced apoptosis in human breast epithelial cells.

Ana Cano-González1, Abelardo López-Rivas2.   

Abstract

Transforming growth factor-beta (TGF-β) induces the epithelial to mesenchymal transition (EMT) in breast epithelial cells and plays an important role in mammary morphogenesis and breast cancer. In non-transformed breast epithelial cells TGF-β antagonizes epidermal growth factor (EGF) action and induces growth inhibition. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been reported to participate in lumen formation during morphogenesis of human breast epithelial cells. Our previous work indicated that sensitivity of human breast epithelial cells to TRAIL can be modulated through the activation of the epidermal growth factor receptor-1 (EGFR). Here, we show that TGF-β opposes EGF-mediated sensitization to TRAIL-induced caspase-8 activation and apoptosis in non-transformed breast epithelial cells. Death-inducing signalling complex (DISC) formation by TRAIL was significantly reduced in cells treated with TGF-β. TGF-β treatment activates cytoprotective autophagy and down-regulates TRAIL-R2 expression at the cell surface by promoting the intracellular accumulation of this receptor. Lastly, we demonstrate that EMT is not involved in the inhibitory effect of TGF-β on apoptosis by TRAIL. Together, the data reveal a fine regulation by EGF and TGF-β of sensitivity of human breast epithelial cells to TRAIL which may be relevant during morphogenesis.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Apoptosis; EGF; Internalization; TGF-β; TRAIL; TRAIL-R2

Mesh:

Substances:

Year:  2016        PMID: 27208428     DOI: 10.1016/j.bbamcr.2016.05.011

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  5 in total

1.  Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis.

Authors:  Italia Grenga; Renee N Donahue; Morgan L Gargulak; Lauren M Lepone; Mario Roselli; Marijo Bilusic; Jeffrey Schlom
Journal:  Urol Oncol       Date:  2017-11-02       Impact factor: 3.498

2.  Expression of microRNA-30c via lentivirus vector inhibits the proliferation and enhances the sensitivity of highly aggressive ccRCC Caki-1 cells to anticancer agents.

Authors:  Honglin Yang; Erlin Song; Guorong Shen; Tonghua Zhu; Tingwang Jiang; Hao Shen; Liping Niu; Biao Wang; Zhaoyang Lu; Jianping Qian
Journal:  Onco Targets Ther       Date:  2017-02-02       Impact factor: 4.147

Review 3.  TRAIL, Wnt, Sonic Hedgehog, TGFβ, and miRNA Signalings Are Potential Targets for Oral Cancer Therapy.

Authors:  Ammad Ahmad Farooqi; Chih-Wen Shu; Hurng-Wern Huang; Hui-Ru Wang; Yung-Ting Chang; Sundas Fayyaz; Shyng-Shiou F Yuan; Jen-Yang Tang; Hsueh-Wei Chang
Journal:  Int J Mol Sci       Date:  2017-07-14       Impact factor: 5.923

Review 4.  Multiple Interactions Between Cancer Cells and the Tumor Microenvironment Modulate TRAIL Signaling: Implications for TRAIL Receptor Targeted Therapy.

Authors:  Margot de Looff; Steven de Jong; Frank A E Kruyt
Journal:  Front Immunol       Date:  2019-07-03       Impact factor: 7.561

Review 5.  Targeting non-coding RNA H19: A potential therapeutic approach in pulmonary diseases.

Authors:  Jinghui Xie; Yuedi Hu; Dengdi Sun; Changan Liu; Zegeng Li; Jie Zhu
Journal:  Front Pharmacol       Date:  2022-09-16       Impact factor: 5.988

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.